Research and Markets: Sales for the Pharmaceutical Company Takeda Increased by 7% to Reach 935,213 Million Yen.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c37825) has announced the addition of the Espicom Business Intelligence Introduction Espicom Business Intelligence is a publisher of independent and impartial information and analysis services focusing on the pharmaceutical and medical device markets. Ltd report: Takeda Pharmaceutical Company Takeda Pharmaceutical Company Limited (武田薬品工業株式会社 Intelligence Report to their offering. Pharmaceutical company intelligence reports provide a full review of the company's activities together with five-year sales forecasts Sales forecast A key input to a firm's financial planning process. External sales forecasts are based on historical experience, statistical analysis, and consideration of various macroeconomic factors. for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events. Topics Covered Latest Results EXECUTIVE SUMMARY PRODUCT PORTFOLIO / RESEARCH & DEVELOPMENT APPENDIX 1 - FINANCIAL PERFORMANCE APPENDIX 2 - KEY CORPORATE EVENTS APPENDIX 3 - KEY AGREEMENTS APPENDIX 4 - INFRASTRUCTURE APPENDIX 5 - KEY PHARMACEUTICAL SUBSIDIARIES/JOINT VENTURES APPENDIX 6 - PRODUCT INDEX Index of Charts Takeda reported net sales Net Sales The amount a seller receives from the buyer after costs associated with the sale are deducted. Notes: This amount is calculated by subtracting the following items from gross sales: merchandise returned for credit, allowances for damaged or missing goods, freight of 935,213 million Yen for the nine months ended 31st December, 2005, a 7% increase over the previous year's corresponding period, supported by higher sales of in-house ethical drugs. The impact of foreign exchange fluctuations increased revenues by 8 billion Yen. Operating income Operating Income The profit realized from a business' own operations. Notes: This would not include income from things such as investments in other firms. Also referred to as operating profit or recurring profit. was up by 2% to 346,584 million Yen, while net income rose by 14% to 281,142 million Yen. Research and development expenditure increased by 36% to 116,056 million Yen. R&D Pipeline Overview Takeda's pipeline is largely dominated by new indications/ formulations for its core products Actos, Takepron, Blopress and Lupron. Encouragingly for the company many of these developments are either awaiting approval or are in late stage Phase III Noun 1. phase III - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the FDA trials. Takeda has also highlighted three novel candidate drugs as future growth drivers: Rozerem, an in-house developed melatonin melatonin: see pineal gland. melatonin Hormone secreted by the pineal gland of most vertebrates. It appears to be important in regulating sleeping cycles; more is produced at night, and test subjects injected with it become sleepy. MT1/MT2 agonist agonist /ag·o·nist/ (ag´ah-nist) 1. one involved in a struggle or competition. 2. agonistic muscle. 3. , was launched in September 2005 and is in Phase III trials in the EU and Japan for insomnia insomnia, abnormal wakefulness or inability to sleep. The condition may result from illness or physical discomfort, or it may be caused by stimulants such as coffee or drugs. However, frequently some psychological factor, such as worry or tension, is the cause. . Lubiprostone has been approved for chronic idiopathic idiopathic /id·io·path·ic/ (id?e-o-path´ik) self-originated; occurring without known cause. id·i·o·path·ic adj. 1. Of or relating to a disease having no known cause; agnogenic. constipation in the US, and has been filed for approval in this indication in Japan. Dimesna, currently in Phase III trials in the US, has been developed by BioNumerik Pharmaceuticals and licensed to Takeda for marketing. Major Products Forecast to 2010 Actos (Diabetes) Basen (Diabetes) Takepron (Gastrointestinal) Blopress (Cardiovascular) Lupron (Cardiovascular) Isovorin (Gastrointestinal) Benet (Musculoskeletal) Seltouch (Musculoskeletal) Companies Mentioned Include: --3M Pharmaceuticals --Abbott --Affymax Inc --Alizyme plc --Andrx Corporation --ASKA Pharmaceutical, KI Pharma --Cerexa Pharmaceuticals Inc --Eli Lilly --Evotec --IL YANG Pharmaceutical Ltd --Kissei Pharmaceutical Co Ltd --Ligand Pharmaceuticals Inc --Merck KGaA --Mitsubishi Pharma Corporation --Paradigm Therapeutics Ltd --PPD Inc --Pronova Biocare AS --Santhera Pharmaceuticals AG --Schering AG --Sucampo Pharmaceuticals Inc --Teijin Limited --Toray Industries Ltd For more information visit http://www.researchandmarkets.com/reports/c37825 |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion